Alexander Stein University Cancer Center Hamburg, Germany

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Advanced breast cancer
Treatment.
Diagnosis.
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Borderline Resectable Pancreatic Carcinoma
Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,
Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.
NSABP PROTOCOL C-10: RESULTS A Phase II Trial of 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) Plus Bevacizumab for Patients with Unresectable.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
DEBATE: What is the Optimal Strategy for Liver Only Metastatic Colon Cancer? Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center.
KRAS Status in Response to Cetuximab
Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Colon Cancer Treatment The Perspective of a Medical Oncologist
Radiofrequency Ablation of Lung Cancer
Associate Professor Winston Liauw Cancer Care Centre St George TREATMENT STRATEGIES TO MAXIMISE PATIENT BENEFIT IN METASTATIC COLORECTAL.
Management of Colorectal Liver Metastasis
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Resection For Lung Metastases M62 Coloproctology Course.
In the name of God Isfahan medical school Shahnaz Aram MD.
Definition of oxaliplatin sensitivity in pts with advanced colorectal cancer previously treated with oxaliplatin-based therapy A. de Gramont, B. Chibaudel,
Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.
COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.
Therapeutic Significance of D-dimer Cut-off Level of more than 3 µg/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab.
Is surgical resection of an asymptomatic primary colorectal tumor beneficial for patients with incurable Stage IV disease? A Phase II Trial of 5-Fluorouracil,
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment.
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.
Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.
EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Pre-Operative Therapy for Borderline Resectable Pancreatic Cancer: The Potential Role of Chemotherapy Robert A. Wolff, M.D. Associate Professor of Medicine.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Colorectal cancer Clinical case scenarios Mixed chemotherapy treatment options Educational Resource February 2012 Updated January 2015 NICE clinical guideline.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
Short-term outcome of neo-adjuvant chemotherapy
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Bronchial Carcinoma Part 2
CUP SSG May 2016 Dr Matt sephton
Neo-adjuvant treatment for metastatic colon cancer in geriatric patients followed by simultaneous hepatic resection: A case report Sotiropoulos GC, Machairas.
Colorectal SSG: SABR and Oligometastatic Disease
TREATMENT ARM B: Cycles 1–3: Cycles 4+: 5-FU continuous infusion
Neoadjuvant Adjuvant Curative Palliative
The role of simultaneous resection of synchronous liver metastasis and primary colorectal cancer Samuel Lo Department of Surgery.
Ali Shamseddine,MD,FRCP
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.
Colorectal Cancer in Older Patients Key Issues
Presentation transcript:

Alexander Stein University Cancer Center Hamburg, Germany ESMO Consensus Conference: Interactive Session on Colorectal Cancer Guidelines A clinical case presentation on advanced colon cancer (first and second line therapy) Alexander Stein University Cancer Center Hamburg, Germany

Disclosure Honoraria from Roche and Merck

Case presentation male, 64 years of age, ECOG 0 no relevant comorbidity routine abdominal ultrasound revealed suspicious liver lesions CT chest/abdomen 3 liver lesions up to 2.5cm 3 suspicious pulmonary lesions up to 1cm single bone lesion 1.8cm mixed osteoplastic/osteolytic (left os ileum) thickening of colonic wall (descendens)

Case presentation colonoscopy: non obstructive tumor without bleeding signs colon descendens histology: adenocarcinoma CEA value 245 ng/ml colon carcinoma with synchronous liver and lung metastates and potential bone involvement

Further diagnostics PET scan  liver and lung lesions positive, bone lesion negative bone scan  weakly positive determination of KRAS status  wildtype ESMO consensus guidelines for management of patients with colon and rectal cancer 2012. KRAS mutation precludes efficacy of treatment with anti-EGFR antibodies and KRAS status determination is therefore mandatory before treatment [I, A].

Acc. to ESMO guidelines next step should be ... start pure palliative chemotherapy for metastatic disease discuss patient within MDT according to clinical presentation and determine treatment aim and clinical grouping

Definition of treatment strategy The optimal strategy should be developed according to the characteristics of the patient and be discussed in the multidisciplinary team and should incorporate the (potential) view of the patient as well. Patients can be individually divided into the 4 clinical groups, by parameters describing localization, extent, and resectability of the disease, tumour dynamics, co-morbidity, potential of the patient to tolerate chemotherapy and secondary surgical treatment [IV, B].

Clinical groups for first line treatment stratification clinical presentation treatment aim treatment intensity clearly R0-resectable liver and/or lung metastases cure, decrease risk of relapse nothing or moderate (FOLFOX) 1 liver and/or lung metastases only which might become resectable after induction chemotherapy ±limited/localized metastases to other sites, e.g. locoregional lymphnodes physically able to undergo major surgery (biological age, heart/lung condition) maximum tumour shrinkage upfront most active combination regimen 2 multiple metastases/sites, with rapid progression and/or tumour-related symptoms/risk of rapid deterioration co-morbidity allows intensive treatment clinically relevant tumour shrinkage as soon as possible at least achieve control of progressive disease upfront active combination: at least doublet 3 never option for resection and/or no major symptoms or risk of rapid deterioration and/or severe comorbidity (excluding from later surgery and/or intensive systemic treatment, as for groups 1+2) abrogation of further progression tumour shrinkage less relevant low toxicity most relevant treatment selection according to disease characteristics and patients preference re toxicity and efficacy: “watchful waiting” sequential approach: start with single agent, or doublet with low toxicity exceptional triplets

Clinical course Patient was considered potentially curative (group 1) by MDT despite the unclear single bone lesion.

Acc. to ESMO guidelines primary tumor should be managed by ... resection of primary tumor before chemotherapy upfront chemotherapy and delayed resection in case of major response (but still unresectable mets) upfront chemotherapy and resection only in case of local symptoms

Clinical course primary tumor was left in situ Potentially resectable metastatic disease after chemotherapy (group 1) For initially unresectable metastatic disease, most active available induction treatment should be chosen [V, C]. If metastases become resectable surgery for primary and metastases should be performed. Palliative surgery, stenting, laser ablation, or (chemo)radiation in case of unresectable disease, even after systemic treatment should be confined to bleeding or obstruction and as minimal invasive as possible and non invasive measures applied first [V, C].

Treatment algorithm for synchronous metastatic colon cancer synchronous metastatic colon cancer with intact primary R0/R1 resectable metastases unresectable metastases single, <2cm liver met 3 months preop FOLFOX intensive upfront chemotherapy resectability achieved? yes no resection of primary and metastases (simultaneous or delayed) continue chemotherapy resectability achieved? 6 months postop FOLFOX 3 months postop FOLFOX continue initial treatment for a total of 6 months yes no surgery of primary: individual decision (e.g. complications or emergency)

Clinical course FOLFOX + bevacizumab restaging after 2/4 months: partial response (RECIST) restaging after 6 months (PET/CT): liver mets: one remaining with 1.4cm (PET positive) lung lesions: complete response bone lesion: unchanged colonoscopy witout macroscopic evidence of residual primary tumor, biopsy negative (local CR) decreased tolerability with peripheral neuropathy G2 and asthenia G1

Clinical course  major response liver and complete response lung-metastases and primary tumor Decision was made by MDT to classify the patient as potentially curative based on age, ECOG, major response and unchanged bone lesion. However, resection or RFA of remaining central liver met. seemed technically difficult.

Further management? maintenance (5FU/Cape and/or bevacizumab) complete stop of treatment consider locally ablative procedure

followed by complete stop of treatment helical tomotherapy with 10x 4Gy for liver metastasis and as a precaution for the bone lesion followed by complete stop of treatment If metastases are not resectable due to their location additional measures like radiofrequency ablation or stereotactic body radiotherapy (in specialized institutions) should be considered, although the benefit is not formally proven [III, B].

Clinical course no evidence of disease for 10 months, followed by progressive disease with 4 new liver and disseminated pulmonary lesions, single bone lesion unchanged remaining toxicity: PNP G1 (12 months after last oxaliplatin administration)

Acc. to ESMO guidelines further treatment should be ... restart FOLFOX + bevacizumab change to irinotecan based second line (FOLFIRI +/- targeted agent)

Reinduction reinduction FOLFOX + bevacizumab In first line treatment patients should be treated as long as possible by restart of the former first line regimen (reinduction), when the toxicity (especially neurotoxicity) allows such reinduction. restaging after 2 months: stable disease restaging after 4 months: progressive disease (multiple new liver lesions)

Further treatment? FOLFIRI + panitumumab FOLFIRI/irinotecan + cetuximab FOLFIRI + bevacizumab (beyond progression - TML) FOLFIRI single agent EGFR antibody

Course of second line FOLFIRI + panitumumab restaging after 3 months: stable disease (SLD -25%), dose reduction FOLFIRI 80% due to neutropenia restaging after 6 months: partial response (SLD -8%) side effects: asthenia G2, cutaneous tox. G1

Thank you